Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency

Inclusion Criteria:

• Patients, male or females aged 18 to 75 years old

• BMI≤40

• Presence of chronic venous insufficiency which is rated between functional classesCEAP 1-4

• Patients diagnosed with superficial vein thrombophlebitis and have skin reaction byredness, swelling, fever and pain symptoms.or patients presenting a painful venoussymptomatology in the lower limbs for at least 30 days.

• Willing and able to give written informed consent prior to participation in the trial

• Patients expected to be compliant with the study treatment

Exclusion Criteria:

• Known allergy to the product's ingredients

• Pregnancy or breastfeeding

• Patient is involved in any other clinical trial

• Deep vein thrombosis

• Stasis dermatitis

• The patient is taking non-steroids anti-inflammatory drugs include oral , topicalcreams or patch form)

• Open ulcers or lower extremity amputation

• Patient treated by venotonic treatments or vascular protectants or assimilated dietarysupplements or homeopathic treatments or diuretics within 15 days prior inclusion

• Patient presenting permanent oedema,

• Patient with a history of lower limbs trauma responsible for sequel pains

• NYHA III and IV Heart Failure

• Renal Failure

• Untreated or uncontrolled Arterial Hypertension

• Hepatic Failure

• History of a known liver disease such as hepatitis A, hepatitis B, or C.

• Malignant neoplasms, from any etiology, or who are receiving any type of anticancertreatment, unless when properly treated and with no evidence of recurrence during thelast five years

• Previous history of alcoholism, drug abuse, psychological or emotional problems in thelast 5 years that can invalidate the Informed Consent Form or restrain participant'sability to comply with the requirements of the protocol.

• Immobility.